Cargando…
Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation
Dual antiplatelet therapy (DAPT) with aspirin and P2Y(12) inhibitor is administered following percutaneous coronary intervention (PCI) with coronary stent implantation. Several studies have reported the effects of switching between P2Y(12) inhibitors on platelet reactivity (P2Y(12) reaction units: P...
Autores principales: | Shimamatsu, Junichiro, Sasaki, Ken-ichiro, Katsuki, Yoshio, Kawasaki, Tomohiro, Murasato, Yoshinobu, Ajisaka, Hidehiko, Yokoi, Hiroyoshi, Tashiro, Hideki, Harada, Atsushi, Hirakawa, Yuji, Ishizaki, Yuta, Ishimatsu, Takashi, Kagiyama, Kotaro, Fukumoto, Yoshihiro, Kakuma, Tatsuyuki, Ueno, Takafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026273/ https://www.ncbi.nlm.nih.gov/pubmed/31549178 http://dx.doi.org/10.1007/s00380-019-01499-7 |
Ejemplares similares
-
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018) -
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
por: Hillegass, William B, et al.
Publicado: (2011) -
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018) -
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada
por: Lordkipanidzé, Marie, et al.
Publicado: (2020) -
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)